Gilead Sciences, IncNasdaq: GILD
Health Care · Biotechnology
$124.38
-4.69%
Vol: 509K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14Gilead posted positive Phase 3 data for a once-weekly oral HIV pill and declared its quarterly dividend, lifting shares.Positive▶
Gilead announced positive topline results from its Phase 3 ISLEND-1 and ISLEND-2 studies of investigational oral once-weekly HIV treatment islatravir/lenacapavir, which met the primary efficacy endpoint with no new safety concerns. The stock rose 3.48% on June 11, 2026 on the pipeline momentum. Gilead also declared a quarterly cash dividend of $0.82 with an ex-date of June 15, 2026. Its HIV franchise, led by Biktarvy, remains the biggest growth engine, and management emphasized no major patent expiries until 2036. Of 31 analysts, the consensus rating is Buy with an average 12-month target of $157.83. The data strengthens Gilead's long-acting HIV pipeline against competition.
May 21Gilead advances HIV pipeline with FDA priority review for bictegravir/lenacapavir combo; Truist raises target to $157.Mixed▶
Gilead Sciences received FDA priority review for its once-daily bictegravir/lenacapavir HIV combination and continued returning capital through share repurchases. The company also filed a $6.51 billion common stock shelf registration to expand financial flexibility. Q1 2026 revenue reached $6.96 billion with net income of $2.02 billion, driven by 8% base business growth led by HIV, oncology, and liver disease. YEZTUGO and TRODELVY outperformed, prompting Gilead to raise 2026 revenue guidance by $400M. However, the company expects a 2026 adjusted loss of $0.65-$1.05/share (vs. prior EPS guidance of $8.45-$8.85) due to large acquisition-related charges. Truist raised target to $157. Average analyst target: $160.50 (~25.6% upside from $127.75). Gilead also extended its WHO collaboration on visceral leishmaniasis with 400,000+ vials of AmBisome donated through 2030.
May 20Gilead Q1 revenue of $6.96B and raised 2026 revenue guidance to $30.2B, but GAAP outlook now reflects loss on Arcellx acquisition charges.Mixed▶
Gilead reported Q1 2026 revenue of $6.96B with 8% YoY growth in the base business and 10% growth in HIV, supported by the launch of Yeztugo. Full-year 2026 revenue guidance was raised to $30.2B; however the company now expects an adjusted 2026 loss of $0.65 to $1.05 per share versus prior adjusted EPS guidance of $8.45-$8.85, reflecting one-time costs tied to the $7.8B Arcellx acquisition. Yeztugo full-year guidance was lifted from $800M to $1B, oncology now exceeds $3B annual run-rate, and Biktarvy holds over 52% U.S. HIV market share. Up to four launches and five Phase 3 updates are anticipated in 2026, including a potential anito-cel fourth-line approval that would validate the Arcellx deal. Jefferies has Buy/$180; Oppenheimer maintains Buy. Risk: integration and dilution from acquisitions plus pipeline binary outcomes.
May 19Gilead to present at RBC Capital Markets Global Healthcare Conference May 19 amid mixed analyst price target movesMixed▶
Gilead executives are scheduled to present at the RBC Capital Markets Global Healthcare Conference on May 19 at 11 a.m. ET and the Bernstein Strategic Decisions Conference on May 28. Q1 2026 results posted revenue of $6.96B and adjusted EPS of $2.03 (vs. $1.91 est.), with raised product sales guidance, though full-year adjusted EPS guidance shifted to a loss of $0.65-$1.05 from prior $8.45-$8.85 due to acquisition-related charges. The company received FDA priority review for its once-daily bictegravir/lenacapavir HIV combination. Truist raised PT to $157 (Buy); Morgan Stanley lowered PT to $168 (Overweight). Risk: large IPR&D charges weigh on GAAP figures even as underlying HIV pipeline strengthens.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15Gilead launches investment-grade bond offering after acquisition spree; FDA accepts bictegravir/lenacapavir HIV NDA with priority reviewMixed▶
Gilead launched its first investment-grade bond offering in 18 months, with notes in up to four tranches and maturities ranging two to eight years, to fund recent multibillion-dollar M&A including the $7.8 billion Arcellx acquisition plus Ouro Medicines and Tubulis. The FDA accepted Gilead's New Drug Application for its once-daily bictegravir/lenacapavir HIV regimen with priority review, a major commercial catalyst. Q1 2026 beat with $6.96B revenue and $2.03 adjusted EPS (vs $1.91 est), driven by 10% HIV growth led by Yeztugo launch and 8% base business growth. Full-year revenue guidance raised to $30.2B midpoint; however, full-year adjusted EPS guidance was lowered to -$0.85 midpoint due to acquisition-related costs (-110% change). Of 32 analysts, 18 Buy, 5 Outperform, 8 Hold, 0 Sell, with ~$158 mean target (~19% upside).
May 14Gilead executives to present at BofA Healthcare Conference May 12; FDA accepted priority review for once-daily bictegravir/lenacapavir HIV NDA; Truist raises PT to $157.Mixed▶
Gilead Sciences presented at the BofA Securities Healthcare Conference on Tuesday, May 12, 2026, with upcoming appearances at RBC Capital Markets Global Healthcare Conference (May 19) and Bernstein Annual Strategic Decisions Conference (May 28). The FDA accepted Gilead's New Drug Application for its once-daily bictegravir/lenacapavir HIV combination regimen with priority review, a key pipeline catalyst. Q1 2026 (reported May 7) revenue grew 4.4% YoY to $6.96B with non-GAAP EPS of $2.03 (beat by 6.3%), though revenue narrowly missed consensus of $7.05B; full-year revenue guidance maintained at ~$30.2B. The company completed a multi-year $4.57B share repurchase program and filed a $6.51B common stock shelf registration. Truist raised PT to $157 from $155. Risk: revised EPS forecast of $(1.05)-$(0.65) reflects substantial acquisition-related charges, creating an earnings optics overhang despite operating strength.
May 13Gilead Sciences shares trade 17% below 52-week high at $131.33 despite Q1 2026 EPS beat; Morgan Stanley cut target to $168 from $175 on May 10.Mixed▶
Gilead reported Q1 2026 revenue of $6.96B (+4.4% YoY) and adjusted EPS of $2.03 (6.3% above consensus), while completing a $4.57B share repurchase program and filing a $6.51B shelf registration. The FDA accepted Gilead's NDA for once-daily bictegravir/lenacapavir HIV regimen with priority review. However, full-year EPS guidance was sharply lowered due to $11.5B in IPR&D acquisition charges. Stock sits 17% below 52-week high of $157.29. Morgan Stanley lowered target to $168 from $175 on May 10. Analyst coverage: 18 Buy, 5 Outperform, 8 Hold.
May 12Gilead Q1 2026 beats with EPS $2.03 vs $1.95 est. on $6.96B revenue; FDA accepts priority review for bictegravir/lenacapavir HIV combo.Mixed▶
Gilead reported Q1 2026 revenue of $6.96B (+4.4% YoY) and non-GAAP EPS of $2.03, beating the $1.95 consensus by $0.08. The FDA accepted Gilead's NDA for its once-daily bictegravir/lenacapavir HIV regimen with priority review, advancing the company's flagship HIV portfolio. Gilead also completed a multi-year $4.57B share repurchase program and filed a $6.51B shelf registration for up to 47.75M common shares, expanding financial flexibility. FY26 revenue guidance is maintained near $30.2B, though EPS guidance was sharply reduced due to large acquisition-related charges. Truist raised its price target to $157 from $155. Executives are presenting at BofA Healthcare (May 12), RBC Global Healthcare (May 19) and Bernstein Strategic Decisions (May 28).
May 11Gilead Q1 beats with $6.96B revenue and raises 2026 sales guidance but cuts EPS outlook to a loss due to acquisition chargesMixed▶
Gilead Sciences reported Q1 2026 revenue of $6.96 billion, up 4.4% YoY, with adjusted EPS of $2.03 beating consensus by 12 cents. The company raised its 2026 revenue outlook by $400M to $30B-$30.4B but now expects an adjusted loss of $1.05 to $0.65 per share, versus prior $8.45-$8.85 profit guidance, due to charges from Arcellx, Ouro Medicines, and Tubulis acquisitions. Sales of HIV prevention drug Yeztugo were raised to $1 billion for 2026. Descovy sales jumped 38% to $807M and Trodelvy rose 37% to $402M. FDA accepted Gilead's NDA for bictegravir/lenacapavir HIV regimen with priority review. Truist raised its price target to $157 from $155.
May 8Gilead beats Q1 2026 with $6.96B revenue and $2.03 EPS; raises 2026 sales guidance to $30.0-$30.4B but guides to annual loss due to $11.5B acquisition charges.Mixed▶
Gilead Sciences reported Q1 2026 revenue of $6.96 billion (beat $6.91B consensus) and adjusted EPS of $2.03 (beat $1.89 consensus). The company raised full-year 2026 sales guidance by $400 million to $30.0-$30.4 billion range but now expects an adjusted loss of $1.05-$0.65 per share (versus prior profit guidance of $8.45-$8.85) due to $11.5 billion in charges and financing costs from acquisitions of Arcellx (cell therapy), Ouro Medicines (autoimmune), and Tubulis (cancer drugs). Key product highlights: Yeztugo (HIV prevention) guidance raised to $1.0B from $800M with Q1 sales of $166M (beat $143M forecast); Descovy (HIV) sales up 38% to $807M; Biktarvy (HIV) up 7% to $3.36B; Trodelvy (cancer) up 37% to $402M. HIV guidance raised to 8% growth from 6%. The stock declined $2.24 to $134.06 on earnings day. Executives presenting at BofA (May 12), RBC Capital Markets (May 19), and Bernstein (May 28) conferences.
May 6Gilead Q1 earnings due May 7; FDA accepts bictegravir/lenacapavir NDA and Tubulis $3B acquisition announcedMixed▶
Gilead Sciences will report Q1 2026 financial results on May 7 after market close. The company recently announced FDA acceptance of its bictegravir and lenacapavir NDA submission on April 29. Gilead agreed to acquire German biotech Tubulis for over $3B and previously closed $7.8B Arcellx acquisition, expanding its oncology pipeline. Q4 2025 revenue was $7.93B (+4.7% YoY); market expects Q1 2026 revenue to grow 2.8% YoY. Morgan Stanley and Wells Fargo reaffirm Buy ratings; Morgan Stanley raised price target to $175 from $171. Stock at $132.46 with analyst consensus cautiously optimistic despite some valuation concerns.
May 5Gilead shareholders approve board and compensation; company acquires Tubulis for $3B to expand oncologyMixed▶
Gilead Sciences held its 2026 annual shareholder meeting on April 30, with investors electing nine directors for one-year terms and approving executive compensation. The FDA accepted Gilead's NDA submission for bictegravir/lenacapivir on April 29. Gilead is pursuing strategic acquisitions including the $3 billion purchase of German biotech Tubulis to expand its oncology pipeline with antibody-drug conjugates. Morgan Stanley reaffirmed its Buy rating with a $175 price target, up from $171, while Citi raised its target to $165 from $156. The company stock has appreciated 25% over the past year despite a recent 6% monthly decline.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABBVABBVIE | $222.45 | +3.70% | +2.4% | 13.2x | 0.30 | $379.0B |
| AMGNAMGEN | $353.95 | +4.90% | +4.0% | 14.4x | 0.43 | $182.2B |
| GILDGILEAD | $124.38 | -4.69% | +0.6% | 13.6x | 0.33 | $162.0B |
| VRTXVERTEX | $445.91 | +2.85% | -0.7% | 20.2x | 0.30 | $110.0B |
| REGNREGENERON | $610.51 | -4.99% | +2.0% | 11.9x | 0.30 | $67.4B |
| BIIBBIOGEN | $197.70 | +4.34% | -1.3% | 11.4x | 0.20 | $28.0B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.